NB-001 Treatment of Recurrent Herpes Labialis

Exclusion Criteria

• •1. Known hypersensitivity to one of the drug ingredients, including soybean oil, polysorbate (Tween), alcohol, EDTA, or cetylpyridinium chloride (found in some mouthwashes and lozenges);
• •2. Severe chronic illness including renal failure, severe respiratory or cardiac disease, chronic infections, immunodeficiency syndrome, uncontrolled diabetes mellitus or untreated severe thyroid disease;
• •3. Received (within the last 6 months) or receiving chemotherapy;
• •4. Significant skin disease on the face (such as atopic dermatitis, cystic acne, severe rosacea, eczema, psoriasis or other chronic vesiculobullous disorders) or lesions, wounds, abrasions, piercings, tattoos, irritation or other skin conditions on or around the nasal and perioral areas that would interfere with the treatment or assessment of the primary lesion complex. Subjects with mild controlled psoriasis, eczema, acne or dermatitis or other conditions may be included if the condition does not interfere with the ability to evaluate a herpes labialis lesion or local skin irritation;
• •5. Previously received herpes vaccine;
• •6. Active alcohol or drug abuse;
• •7. Prior randomization into any NanoBio study;
• •8. Any condition that would potentially make them unable to participate for the entire trial period;
• •9. Known allergies to topical creams, ointments or other topical medications.